Ameya Puranik

Employment

• Tata Memorial Centre Professor

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (9)

• PReCedeNT trial: Phase III randomized-controlled trial of Lutetium − 177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) plus Chemotherapy versus PRRT alone in FDG-avid, Well-differentiated Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
  BMC Cancer 2025 DOI: 10.1186/s12885-025-15111-x
  +Save
• Frontiers in radiopharmaceuticals for neuroendocrine tumors
  Journal of Neuroendocrinology 2025 DOI: 10.1111/jne.70006
  +Save
• Theranostics in Lung Neuroendocrine Tumors
  Seminars in Nuclear Medicine 2025 DOI: 10.1053/j.semnuclmed.2025.02.010
  +Save
• FET PET to differentiate between post-treatment changes and recurrence in high-grade gliomas: a single center multidisciplinary clinic controlled study
  Neuroradiology 2025 DOI: 10.1007/s00234-024-03495-9
  +Save
• Current and Future Perspectives of PDL1 PET and SPECT Imaging
  Seminars in Nuclear Medicine 2024 DOI: 10.1053/j.semnuclmed.2024.09.008
  +Save
• Molecular Imaging of Glial Tumors: Established and Emerging Tracers
  Indian Journal of Neurosurgery 2023 DOI: 10.1055/s-0043-1770910
  +Save
• Imaging-Based Patterns of Failure following Re-Irradiation for Recurrent/Progressive High-Grade Glioma
  Journal of Personalized Medicine 2023 DOI: 10.3390/jpm13040685
  +Save
• Brain FET PET tumor‐to‐white mater ratio to differentiate recurrence from post‐treatment changes in high‐grade gliomas
  Journal of Neuroimaging 2021 DOI: 10.1111/jon.12914
  +Save
• Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer
  Cancers 2021 DOI: 10.3390/cancers13143607
  +Save